Lerna Biopharma to Present New siRNA Therapy for Liver Failure

Lerna Biopharma, a Singapore, Boston, Shanghai company, will present its lead drug, a first-in-class siRNA that promotes liver regeneration in patients at risk for liver failure. The candidate, LR1, takes advantage of the liver’s ability to heal itself, a long-sought goal. In preclinical testing, LR1 improved liver function and protected the liver from further degeneration. Lerna discovered the novel target using its Quartz platform, which discovers novel targets that are usually unavailable but can be addressed by siRNA technology. Lerna will describe the novel siRNA candidate at a Boston scientific convention, The Liver Meeting, later this week. More details...

Share this with colleagues: